APO RESEARCH · REPORT
Overactive Bladder Treatment
Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.
Product & engineering
Understand the product.
Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.
Selected research
Industry Research
Overactive Bladder Treatment Industry Research Report 2026
Market perspective
Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.
Global Overactive Bladder Treatment key players include Allergan, Astellas Pharma, Pfizer, Johnson & Johnson, Medtronic, etc. Global top five manufacturers hold a share about 90%. United States is the largest market, with a share about 60%, followed by Europe, with a share about 15 percent. In terms of product, Drugs is the largest segment, with a share about 95%. And in terms of application, the largest application is Idiopathic Overactive Bladder, followed by Neurogenic Overactive Bladder.
Report Scope
Read the full market overview
This report quantifies the global Overactive Bladder Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Overactive Bladder Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Overactive Bladder Treatment Market by Company
Allergan
Astellas Pharma
Pfizer
Johnson & Johnson
Medtronic
KYORIN Pharmaceutical
Overactive Bladder Treatment Segment by Type
Drugs
Device
Overactive Bladder Treatment Segment by Application
Idiopathic Overactive Bladder
Neurogenic Overactive Bladder
Overactive Bladder Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Overactive Bladder Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drugs
- Device
Applications
- Idiopathic Overactive Bladder
- Neurogenic Overactive Bladder
Companies covered
- Allergan
- Astellas Pharma
- Pfizer
- Johnson & Johnson
- Medtronic
- KYORIN Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Overactive Bladder Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drugs
- 2.2.3 Device
- 2.3 Overactive Bladder Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Idiopathic Overactive Bladder
- 2.3.3 Neurogenic Overactive Bladder
- 2.4 Assumptions and Limitations
3 Overactive Bladder Treatment Breakdown Data by Type
- 3.1 Global Overactive Bladder Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Overactive Bladder Treatment Forecasted Market Size by Type (2027-2032)
4 Overactive Bladder Treatment Breakdown Data by Application
- 4.1 Global Overactive Bladder Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Overactive Bladder Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Overactive Bladder Treatment Market Perspective (2021-2032)
- 5.2 Global Overactive Bladder Treatment Growth Trends by Region
- 5.2.1 Global Overactive Bladder Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Overactive Bladder Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Overactive Bladder Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Overactive Bladder Treatment Market Dynamics
- 5.3.1 Overactive Bladder Treatment Industry Trends
- 5.3.2 Overactive Bladder Treatment Market Drivers
- 5.3.3 Overactive Bladder Treatment Market Challenges
- 5.3.4 Overactive Bladder Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Overactive Bladder Treatment Players by Revenue
- 6.1.1 Global Top Overactive Bladder Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Overactive Bladder Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Overactive Bladder Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Overactive Bladder Treatment Head Office and Area Served
- 6.4 Global Overactive Bladder Treatment Players, Product Type & Application
- 6.5 Global Overactive Bladder Treatment Manufacturers Established Date
- 6.6 Global Overactive Bladder Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Overactive Bladder Treatment Market Size (2021-2032)
- 7.2 North America Overactive Bladder Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Overactive Bladder Treatment Market Size by Country (2021-2026)
- 7.4 North America Overactive Bladder Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Overactive Bladder Treatment Market Size (2021-2032)
- 8.2 Europe Overactive Bladder Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Overactive Bladder Treatment Market Size by Country (2021-2026)
- 8.4 Europe Overactive Bladder Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Overactive Bladder Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Overactive Bladder Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Overactive Bladder Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Overactive Bladder Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Overactive Bladder Treatment Market Size (2021-2032)
- 10.2 South America Overactive Bladder Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Overactive Bladder Treatment Market Size by Country (2021-2026)
- 10.4 South America Overactive Bladder Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Overactive Bladder Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Overactive Bladder Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Overactive Bladder Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Overactive Bladder Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Allergan
- 12.1.1 Allergan Company Information
- 12.1.2 Allergan Business Overview
- 12.1.3 Allergan Revenue in Overactive Bladder Treatment Business (2021-2026)
- 12.1.4 Allergan Overactive Bladder Treatment Product Portfolio
- 12.1.5 Allergan Recent Developments
- 12.2 Astellas Pharma
- 12.2.1 Astellas Pharma Company Information
- 12.2.2 Astellas Pharma Business Overview
- 12.2.3 Astellas Pharma Revenue in Overactive Bladder Treatment Business (2021-2026)
- 12.2.4 Astellas Pharma Overactive Bladder Treatment Product Portfolio
- 12.2.5 Astellas Pharma Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Overactive Bladder Treatment Business (2021-2026)
- 12.3.4 Pfizer Overactive Bladder Treatment Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 Johnson & Johnson
- 12.4.1 Johnson & Johnson Company Information
- 12.4.2 Johnson & Johnson Business Overview
- 12.4.3 Johnson & Johnson Revenue in Overactive Bladder Treatment Business (2021-2026)
- 12.4.4 Johnson & Johnson Overactive Bladder Treatment Product Portfolio
- 12.4.5 Johnson & Johnson Recent Developments
- 12.5 Medtronic
- 12.5.1 Medtronic Company Information
- 12.5.2 Medtronic Business Overview
- 12.5.3 Medtronic Revenue in Overactive Bladder Treatment Business (2021-2026)
- 12.5.4 Medtronic Overactive Bladder Treatment Product Portfolio
- 12.5.5 Medtronic Recent Developments
- 12.6 KYORIN Pharmaceutical
- 12.6.1 KYORIN Pharmaceutical Company Information
- 12.6.2 KYORIN Pharmaceutical Business Overview
- 12.6.3 KYORIN Pharmaceutical Revenue in Overactive Bladder Treatment Business (2021-2026)
- 12.6.4 KYORIN Pharmaceutical Overactive Bladder Treatment Product Portfolio
- 12.6.5 KYORIN Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst